Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models

• Published in: Cancer letters Vol. 339; no. 1; pp. 42 - 48
• Main Authors: Luo, Ke-Wang, Ko, Chun-Hay, Yue, Grace G.L, Lee, Michelle Y.Y, Siu, Wing-Sum, Lee, Julia K.M, Shum, Wai-Ting, Fung, Kwok-Pui, Leung, Ping-Chung, Li, Gang, Evdokiou, Andreas, Lau, Clara B.S
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 01.10.2013; Elsevier Limited
• Subjects: Acids; Administration, Metronomic; animal models; Animals; Anti-osteolysis; Antineoplastic Agents - administration & dosage; Bioluminescence; Bone and Bones - diagnostic imaging; Bone and Bones - pathology; Bone cancer; Bone Density Conservation Agents - administration & dosage; Breast cancer; breast neoplasms; Cell adhesion & migration; Conventional; Diphosphonates - administration & dosage; Drug dosages; Female; Fractures; Hematology, Oncology and Palliative Medicine; Humans; Imidazoles - administration & dosage; Laboratory animals; Liver; Mammary Neoplasms, Experimental - diagnostic imaging; Mammary Neoplasms, Experimental - drug therapy; Mammary Neoplasms, Experimental - pathology; Medical imaging; Metastasis; Metronomic; Mice; Mortality; Neoplasm Metastasis; Osteolysis - diagnostic imaging; Osteolysis - drug therapy; Osteolysis - etiology; Osteolysis - pathology; Radiography; Rodents; Spinal cord; Tomography; Tumor Burden - drug effects; Zoledronic acid; Zoledronic acid; Anti-osteolysis; Metastasis; Metronomic; Conventional
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2013.07.024

Highlights • Metronomic ZOL on tumor growth and osteolysis in breast cancer mice were studied. • Metronomic ZOL (zoledronic acid) resulted in a significant reduction of tumor burden. • Metronomic ZOL did not promote lung or liver metastasis. • Metronomic ZOL protected the bone from breast cancer-induced osteolysis. • This dosing schedule of ZOL showed great potential against metastatic breast cancer.